Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published April 15, 2007 | Supplemental Material
Journal Article Open

ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia

Abstract

In 15% to 30% of patients with acute myeloid leukemia (AML), aberrant proliferation is a consequence of a juxtamembrane mutation in the FLT3 gene (FMS-like tyrosine kinase 3–internal tandem duplication [FLT3-ITD]), causing constitutive kinase activity. ABT-869 (a multitargeted receptor tyrosine kinase inhibitor) inhibited the phosphorylation of FLT3, STAT5, and ERK, as well as Pim-1 expression in MV-4-11 and MOLM-13 cells (IC_(50) approximately 1-10 nM) harboring the FLT3-ITD. ABT-869 inhibited the proliferation of these cells (IC_(50) = 4 and 6 nM, respectively) through the induction of apoptosis (increased sub-G_(0)/G_1 phase, caspase activation, and PARP cleavage), whereas cells harboring wild-type (wt)–FLT3 were less sensitive. In normal human blood spiked with AML cells, ABT-869 inhibited phosphorylation of FLT3 (IC_(50) approximately 100 nM), STAT5, and ERK, and decreased Pim-1 expression. In methylcellulose-based colony-forming assays, ABT-869 had no significant effect up to 1000 nM on normal hematopoietic progenitor cells, whereas in AML patient samples harboring both FLT3-ITD and wt-FLT3, ABT-869 inhibited colony formation (IC_(50) = 100 and 1000 nM, respectively). ABT-869 dose-dependently inhibited MV-4-11 and MOLM-13 flank tumor growth, prevented tumor formation, regressed established MV-4-11 xenografts, and increased survival by 20 weeks in an MV-4-11 engraftment model. In tumors, ABT-869 inhibited FLT3 phosphorylation, induced apoptosis (transferase-mediated dUTP nick-end labeling [TUNEL]) and decreased proliferation (Ki67). ABT-869 is under clinical development for AML.

Additional Information

© 2007 American Society of Hematology. Submitted June 15, 2006; accepted December 9, 2006. D.B.S. is supported by the Hamburger endowment from the UCLA Jonsson Comprehensive Cancer Center. K.M.S. is a Scholar of the Lymphoma and Leukemia Society and is supported by the NIH (CA108545, HL75826, RHL083077A), the Department of Defense and the Diamond-Blackfan Anemia Foundation. Both T.B.M. and K.M.S. are funded by the UCLA Jonsson Comprehensive Cancer Center.

Attached Files

Supplemental Material - 1.pdf

Supplemental Material - 2.pdf

Supplemental Material - 3.pdf

Files

1.pdf
Files (80.6 kB)
Name Size Download all
md5:d4b3de7c2f967530dece6cd611696d35
11.3 kB Preview Download
md5:a914086c3619019c9229963ccadae0d6
38.8 kB Preview Download
md5:dbcd6de0924c0d11faa0c29df39464a2
30.4 kB Preview Download

Additional details

Created:
August 19, 2023
Modified:
October 19, 2023